Company intelligence / Profile preview

AlloCure

Burlington, Massachusetts, United Statesallocure.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

AlloCure developed AC607, an off-the-shelf allogeneic MSC therapy for acute kidney injury. The company completed a successful Phase I trial showing safety and encouraging efficacy signals. A large multicenter randomized double-blind placebo-controlled Phase II trial was launched to further evaluate efficacy in post-cardiac surgery AKI patients. No approved therapies exist for AKI beyond supportive care at the time of these studies. The company received FDA Fast Track designation for AC607 in this indication. As of the latest reports, no commercial product has been launched.

Therapeutic areas: OtherNephrology
Modalities: Cell therapyspecifically allogeneic mesenchymal stem cells (MSCs)
Industry: Biotech

Drug pipeline

1 asset

AC607

Discontinued

Partnerships

Academic institutions/hospitals participating in ACT-AKI multicenter trial

Beyond the preview

Go deeper on AlloCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlloCure.